With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

The ongoing COMPANION-002 trial has been evaluating the candidate, tovecimig (formerly CTX-009), alongside paclitaxel in ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 ...

This milestone marks Context’s second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 (“CLDN6”) x CD3 TCE bispecific ...